An appraisal of antifungal impacts of nano-liposome containing voriconazole on voriconazole-resistant Aspergillus flavus isolates as a groundbreaking drug delivery system

Authors

  • Adel Spotin Department of Parasitology and Mycology, Faculty of medicine, Tabriz University of Medical Sciences, Tabriz, Iran. | Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
  • Behzad Baradaran Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
  • Hamed Hamishehkar Drug Applied Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
  • Maryam Mohammadi Drug Applied Research Center, Tabriz University of Medical Sciences, Tabriz, Iran. | Biotechnology research center and student research committee, Tabriz University of Medical Sciences, Tabriz, Iran.
  • Navid Shomali Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran. | Student Research Committee, Tabriz University of Medical Sciences, Tabriz, Iran.
  • Parviz Hassanpour Department of Parasitology and Mycology, Faculty of medicine, Tabriz University of Medical Sciences, Tabriz, Iran.
  • Sanam Nami Department of Parasitology and Mycology, Faculty of medicine, Tabriz University of Medical Sciences, Tabriz, Iran. | Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
  • Teimour Hazratian Department of Parasitology and Mycology, Faculty of medicine, Tabriz University of Medical Sciences, Tabriz, Iran.
Abstract:

Background: This study is an attempt to investigate the effect of nano-liposome containing voriconazole on voriconazole-resistant A. flavus strains on the one hand, and to consider the expression of cyp51A and MDR1genes, regarded as important genes involved in the development of resistance to triazoles before and after voriconazole and voriconazole-loaded nano-liposomes exert their effects, on the other hand.Methods: Strains of A. flavus isolated from patients were investigated and their susceptibility to voriconazole was determined. Next, having applied a slight modification to the thin film hydration-sonication technique, the liposomal formulation of voriconazole was produced. After that, the voriconazole-loaded nano-liposome was subjected to in-vitro antifungal susceptibility testing to obtain minimum inhibitory concentration against fungal isolates. Cyp51A and MDR1 mRNA levels were amplified by qRT-PCR instrument.Results: The effect of nano-liposome containing voriconazole on the reduction of MIC in A. flavus isolates were considered to be significant. After using MIC50 concentration of VCZ, the cyp51A gene expression in voriconazole-susceptible A. flavus strains and voriconazole-resistant strains 10folds and 7folds depicted a downregulation, respectively, which was more pronounced in the expression of a liposomal formulation of VCZ (13folds and 15folds respectively). Identically, the same procedure was applied to MDR1, even though it induced 1, 2, 3, 4-fold reductions.Conclusion: Considering the benefits of liposome-containing voriconazole formulation, such as the reduction of the side effects of the pure drug as well as minimizing the drug's toxicity coupled with the enhanced drug bioavailability and stability, the formulation can be used in drug-sensitive and drug-resistant species.

Upgrade to premium to download articles

Sign up to access the full text

Already have an account?login

similar resources

Voriconazole: a new triazole antifungal.

OBJECTIVE To review the currently available information on the pharmacology, pharmacokinetics, efficacy, adverse effects, drug interactions, and dosage guidelines of voriconazole. Comparative data for voriconazole and other azole antifungal agents are described where available. DATA SOURCES A MEDLINE search restricted to English-language articles (1966 to September 1999) was conducted, and an...

full text

ارزیابی حساسیت دارویی وریکونازول و ایتراکونازول نسبت به 90 ایزوله محیطی و بالینی آسپرژیلوس فلاووس

Background and purpose: Invasive aspergillosis (IA) is a leading cause of morbidity and mortality in patients with decreased immune status. Aspergillus flavus is the second most common species causing invasive aspergillosis after A. fumigatus. According to limited information on the antifungal susceptibility test against A. flavus in Iran, in this study we aimed at evaluating the antifungal sus...

full text

Avian Aspergillus fumigatus strains resistant to both itraconazole and voriconazole.

The in vitro susceptibilities of 59 avian Aspergillus fumigatus strains to amphotericin B, itraconazole, and voriconazole were determined using the standard microdilution broth method (CLSI M38-A2). Four isolates showed acquired resistance to itraconazole and voriconazole, harboring implications for the treatment of aspergillosis in both birds and humans.

full text

The Utilization of RNA Silencing Technology to Mitigate the Voriconazole Resistance of Aspergillus Flavus; Lipofectamine-Based Delivery

Purpose: Introducing the effect of RNAi in fungi to downregulate essential genes has made it a powerful tool to investigate gene function, with potential strategies for novel disease treatments. Thus, this study is an endeavor to delve into the silencing potentials of siRNA on cyp51A and MDR1 in voriconazole-resistant Aspergillus flavus as the target genes. Methods: In this study, we designed t...

full text

Voriconazole: a new triazole antifungal agent.

Voriconazole is a second-generation azole antifungal agent that shows excellent in vitro activity against a wide variety of yeasts and molds. It can be given by either the intravenous or the oral route; the oral formulation has excellent bioavailability. The side effect profile of voriconazole is unique in that non-sight-threatening, transient visual disturbances occur in approximately 30% of p...

full text

Multidrug-resistant Trichosporon asahii isolates are susceptible to voriconazole.

We recently described the recovery of six clinical isolates of Trichosporon asahii from nongranulocytopenic patients that exhibited reduced susceptibilities to amphotericin B, flucytosine, ketoconazole, itraconazole, and fluconazole (7). In a recent paper Paphitou et al. reported (6) that the new investigational triazoles including voriconazole were highly potent against 24 isolates of Trichosp...

full text

My Resources

Save resource for easier access later

Save to my library Already added to my library

{@ msg_add @}


Journal title

volume 5  issue 1

pages  90- 100

publication date 2020-03-01

By following a journal you will be notified via email when a new issue of this journal is published.

Hosted on Doprax cloud platform doprax.com

copyright © 2015-2023